Skip to main content

Table 2 Summary of biopsy cores

From: Clinically significant prostate cancer (csPCa) detection with various prostate sampling schemes based on different csPCa definitions

 

SB

TB

ipsi-SB + TB

contra-SB + TB

SB + TB

Biopsy cores, no

10 (10–10)

2 (2–2)

7 (7–7)

7 (7–7)

12 (12–12)

Positive biopsy cores, no

1 (0–4)

0 (0–2)

2 (0–5)

2 (0–3)

2 (0–6)

D1 positive core rate, n (%)

373 (10.69)

230 (29.72)

509 (20.21)

324 (12.86)

603 (14.14)

P

 < 0.001

 < 0.001

 < 0.001

0.017

–

D2 positive core rate, n (%)

678 (19.43)

357 (46.12)

817 (32.43)

575 (22.83)

1035 (24.27)

P

 < 0.001

 < 0.001

 < 0.001

0.051

–

  1. Values are presented as median (interquartile range). Statistically significant at P < 0.05. SB, systematic biopsy; TB, targeted biopsy; ipsi-SB, ipsilateral SB; contra-SB, contralateral SB; D1, definition 1 (EAU guidelines); csPCa, clinically significant prostate cancer; D2, definition 2 (Epstein criteria)